Literature DB >> 33087396

Mechanism of Diuresis and Natriuresis by Cannabinoids: Evidence for Inhibition of Na+-K+-ATPase in Mouse Kidney Thick Ascending Limb Tubules.

Joseph K Ritter1, Ashfaq Ahmad2, Shobha Mummalaneni2, Zdravka Daneva2, Sara K Dempsey2, Ningjun Li2, Pin-Lan Li2, Vijay Lyall2.   

Abstract

The endocannabinoid, anandamide (AEA), stimulates cannabinoid receptors (CBRs) and is enriched in the kidney, especially the renal medulla. AEA infused into the renal outer medulla of mice stimulates urine flow rate and salt excretion. Here we show that these effects are blocked by the CBR type 1 (CB1) inverse agonist, rimonabant. Immunohistochemical analysis demonstrated the presence of CB1 in thick ascending limb (TAL) tubules. Western immunoblotting demonstrated the presence of CB1 (52 kDa) in the cortex and outer medulla of mouse kidney. The effect of direct [CP55940 (CP) or AEA] or indirect [fatty acyl amide hydrolase (FAAH) inhibitor, PF3845 (PF)] cannabinoidimetics on Na+ transport in isolated mouse TAL tubules was studied using the Na+-sensitive dye, SBFI-AM. Switching from 0 Na+ solution to control Ringer's solution (CR) rapidly increased TAL cell [Na+]i Addition of CP to CR produced a further elevation, similar in magnitude to that of ouabain, a Na+-K+-ATPase inhibitor. This [Na+]i-elevating effect of CP was time-dependent, required the presence of Na+ in the bathing solution, and was insensitive to Na+-K+-2Cl- cotransporter inhibition. Addition of PF to CR elevated [Na+]i in FAAH wild-type but not FAAH knockout (KO) TALs, whereas the additions of CP and AEA to PF-treated FAAH KO TALs increased [Na+]i An interaction between cannabinoidimetics and ouabain (Ou) was observed. Ou produced less increase in [Na+]i after cannabinoidimetic treatment, whereas cannabinoidimetics had less effect after Ou treatment. It is concluded that cannabinoidimetics, including CP and AEA, inhibit Na+ transport in TALs by inhibiting Na+ exit via Na+-K+-ATPase. SIGNIFICANCE STATEMENT: Cannabinoids including endocannabinoids induce renal urine and salt excretion and are proposed to play a physiological role in the regulation of blood pressure. Our data suggest that the mechanism of the cannabinoids involves inhibition of the sodium pump, Na+-K+-ATPase, in thick ascending limb cells and, likely, other proximal and distal tubular segments of the kidney nephron.
Copyright © 2020 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33087396      PMCID: PMC7745087          DOI: 10.1124/jpet.120.000163

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  27 in total

1.  Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion.

Authors:  N L Benowitz; R T Jones
Journal:  Clin Pharmacol Ther       Date:  1975-09       Impact factor: 6.875

2.  Intracellular cannabinoid type 1 (CB1) receptors are activated by anandamide.

Authors:  G Cristina Brailoiu; Tudor I Oprea; Pingwei Zhao; Mary E Abood; Eugen Brailoiu
Journal:  J Biol Chem       Date:  2011-06-30       Impact factor: 5.157

3.  Modulation of mean arterial pressure and diuresis by renomedullary infusion of a selective inhibitor of fatty acid amide hydrolase.

Authors:  Ashfaq Ahmad; Sara K Dempsey; Zdravka Daneva; Ningjun Li; Justin L Poklis; Pin-Lan Li; Joseph K Ritter
Journal:  Am J Physiol Renal Physiol       Date:  2018-05-30

4.  Combination of rimonabant and donepezil prolongs spatial memory duration.

Authors:  Laura E Wise; Philip A Iredale; Rene J Stokes; Aron H Lichtman
Journal:  Neuropsychopharmacology       Date:  2007-01-10       Impact factor: 7.853

5.  Role of the central autonomic nervous system in the hypotension and bradycardia induced by (-)-delta 9-trans-tetrahydrocannabinol.

Authors:  R R Vollmer; I Cavero; R J Ertel; T A Solomon; J P Buckley
Journal:  J Pharm Pharmacol       Date:  1974-03       Impact factor: 3.765

6.  Internalization and recycling of the CB1 cannabinoid receptor.

Authors:  C Hsieh; S Brown; C Derleth; K Mackie
Journal:  J Neurochem       Date:  1999-08       Impact factor: 5.372

7.  Production and actions of the anandamide metabolite prostamide E2 in the renal medulla.

Authors:  Joseph K Ritter; Cao Li; Min Xia; Justin L Poklis; Aron H Lichtman; Rehab A Abdullah; William L Dewey; Pin-Lan Li
Journal:  J Pharmacol Exp Ther       Date:  2012-06-08       Impact factor: 4.030

Review 8.  Pharmacology of cannabinoid receptor ligands.

Authors:  R G Pertwee
Journal:  Curr Med Chem       Date:  1999-08       Impact factor: 4.530

9.  Diuretic effects of cannabinoid agonists in mice.

Authors:  Girish R Chopda; V Kiran Vemuri; Rishi Sharma; Ganesh A Thakur; Alexandros Makriyannis; Carol A Paronis
Journal:  Eur J Pharmacol       Date:  2013-10-05       Impact factor: 4.432

10.  Comparative diuretic activity of delta9-tetrahydrocannabinol, cannabidiol, cannabinol and hydrochlorothiazide in the rat.

Authors:  R D Sofia; L C Knobloch; J J Harakal; D J Erikson
Journal:  Arch Int Pharmacodyn Ther       Date:  1977-01
View more
  1 in total

Review 1.  Cannabinoid Receptor 1 Inhibition in Chronic Kidney Disease: A New Therapeutic Toolbox.

Authors:  Myriam Dao; Helene François
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-07       Impact factor: 5.555

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.